Shandong Buchang Pharmaceuticals Co., Ltd.

The company's own disclosures show revenue comes from outright product sales, recognized once goods are delivered under contract terms, rather than from subscriptions, royalties or usage-based fees. Most of that revenue sits in one therapeutic category, treatments for heart and blood-vessel conditions, with the remaining categories each contributing smaller, more scattered amounts.

This company operates in the same basic way as a large number of other drug producers that CompanyGraph tracks, so its scale is not unusual within that group. CompanyGraph's own recalculation of its reported financial statements also shows profit has not grown smoothly alongside revenue, swinging between gains and losses in more than one recent year.

The company's own disclosures show it depends on a steady supply of traditional Chinese medicinal raw materials, including named herbs and animal-derived materials such as notoginseng, Salvia and leech, some of which it sources from its own growing bases and the rest through market-price purchase contracts with outside suppliers. It also depends on approval and ongoing oversight from China's national drug regulator before its medicines can be manufactured and sold.

The company's own disclosures show its direct customers are distributors rather than patients or hospitals, and that a small number of these distributor customers account for much of its total sales, so a relatively narrow set of counterparties carries a large share of its revenue collection.

The company attributes its position to its own patents, its brand history and an academic-promotion approach built around a proprietary heart-and-brain treatment theory, and cites outside data placing it first by combined sales share in one medicine category; these are the company's own claims, not independently confirmed by CompanyGraph. It also operates in the same basic way as a large number of other companies CompanyGraph tracks, so that alone does not set it apart.

The company states that its own growth is limited less by production capacity than by its organizational design, management systems and its ability to attract technical and management talent as it expands, and separately says that modernizing traditional Chinese medicine is slowed by the field's lack of a unified basic theory and settled quality and diagnostic standards.

The company states that its named products, Naoxintong Capsules, Wenxin Granules and Danhong Injection, contribute a relatively large share of its performance, and that a small number of distributor customers account for much of its sales, so both its product mix and its customer base are concentrated. It also names goodwill impairment and competition from large international drug makers among the first risks it lists for itself.

The company names competition from large multinational drug makers, the slow scientific modernization of traditional Chinese medicine, and shifting health policy among the pressures it faces, and discloses an active contract dispute in court. It also reports a small amount of foreign-currency exposure and operates its manufacturing and product registration under national drug-regulatory oversight.